Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing
For the third time this year, Novartis has been rebuked by a U.K. trade group for misleading promotional efforts for its biggest-selling drug.
For the third time this year, Novartis has been rebuked by a U.K. trade group for misleading promotional efforts for its biggest-selling drug.
Pfizer agreed to settle more than 10,000 cases accusing it of hiding cancer risks of its Zantac heartburn drug.
A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
The FTC wants more information on a $16.5 million deal in which Novo Nordisk’s parent company would purchase Catalent, a contract drug manufacturer.
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
The move by the California Supreme Court to review the case is seen as “very important,” according Evercore ISI analyst Umer Raffat.
The move by the California Supreme Court to review the case is seen as “very important,” according Evercore ISI analyst Umer Raffat.
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to…
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.
A controversial provision of a federal law designed to speed copycat drugs to market and foster competition saved Medicare Part D nearly $15 billion from